US EditionCelebrating 2 years on Yorvipath, my hypoparathyroidism treatment
Summary by Hypoparathyroidism News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Celebrating 2 years on Yorvipath, my hypoparathyroidism treatment
When I was a teenager, adults used to tell me time sped up every year. I scoffed in that way kids do when they don’t believe an adult, but I swear these days that time is nonsensical. This week marks my two-year anniversary on Yorvipath (palopegteriparatide), the first and only treatment approved by the U.S. Food and Drug Administration for hypoparathyroidism. It somehow feels like a lifetime ago and just last week. Looking back over the last tw…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
